L-肉碱预处理对离体家兔心肌缺血再灌注损伤的保护作用

目的:观察L-肉碱预处理对离体家兔心肌缺血再灌注损伤的保护作用.方法:采用离体兔心Langendorff灌注实验模型,离体兔心24只,随机等分成3组(n=8).正常对照组:连续灌注K-H液 90 min;缺血再灌注损伤组:灌注 30 min,关闭主动脉套管停止灌注,30 min后恢复37 ℃ K-H液灌注 60 min;L-肉碱组:步骤同缺血再灌注组,但在停灌前先用含10 mmolL-1 L-肉碱的K-H液灌注 30min.记录血流动力学指标:冠脉流量(CF)、左心室舒张压(LVDP)、左心室压力时间变化率(±dp/dt);检测冠脉流出液中丙二醛(MDA)、超氧化物歧化酶(SOD)、肌酸激酶(CK)、乳酸脱氢酶(LDH)浓度和心肌组织中MDA、SOD及L-肉碱的含量.结果:L-肉碱组能显著促进再灌注时心功能恢复:±dp/dtmax和LVDP显著升高;CF增大;冠脉流出液中MDA、LDH、CK以及心肌组织中MDA浓度降低;而冠脉流出液和心肌组织中SOD含量均升高(P<0.05);心肌中L-肉碱含量明显增高(P<0.01);超微结构观察结构损伤较轻(P<0.05).结论:L-肉碱预处理具有抗兔离体心肌缺血再灌注损伤的作用.     

参麦注射液对正常及缺血再灌注离体豚鼠心脏的影响

目的观察参麦注射液(SM)对正常及缺血再灌注离体豚鼠心脏的影响。方法采用正常Langendorff灌流及缺血再灌注离体豚鼠心脏模型,观察SM对冠脉流量的影响,测定冠脉流出液中乳酸脱氢酶(LDH)活性及心肌组织丙二醛(MDA)、超氧化物歧化酶(SOD)的活性。结果SM可显著提高正常及缺血-再灌注离体豚鼠心脏的冠脉流量,减少缺血-再灌注后LDH的漏出总量,降低缺血再灌后心肌组织MDA的含量,升高SOD的活性。结论SM可增加正常及缺血-再灌离体豚鼠心脏冠脉流量,减轻缺血-再灌引起的心肌损伤。     

咖啡酸苯乙酯对大鼠离体心脏心肌缺血再灌注的保护作用北大核心CSCD

目的建立大鼠离体心脏心肌缺血再灌注模型,初步探讨咖啡酸苯乙酯对离体心脏心肌缺血再灌注损伤的保护作用。方法雄性SD大鼠30只,取心脏Langendorff法离体灌流,实验分5组:空白组:KH(Krebs-Henseleit)液连续灌流100 min;模型组:KH液稳灌30 min后停灌30 min,再灌注KH液40 min;给药组:KH液稳灌30 min后,停灌30 min,再灌注3、6和12 mg/L CAPE的KH液40min。实验中观察各组大鼠离体心脏的冠脉流量、心肌收缩力及心率的变化。停灌后测其各组心肌组织的丙二醛(MDA)、蛋白羰基化(PCO)的含量和超氧化物歧化酶(SOD)活性。结果心脏缺血再灌注期间,模型组收缩力减弱,张力增加,心率减慢,冠脉流量明显减少,出现心律失常;给药组在再灌注后收缩力增强,张力降低,心率增快,冠脉流量明显增加,节律整齐。停灌后模型组MDA、PCO含量明显升高,SOD含量降低,而给药组MDA、PCO的含量较模型组减少(P<0.01),且减少SOD含量的降低(P<0.01)。说明缺血再灌注能够增加心脏的氧化应激,诱导氧化损伤,CAPE保护可以减少氧化损伤,且呈剂量依赖性。结论咖啡酸苯乙酯对大鼠离体心脏缺血再灌注损伤具有保护作用,其机制可能与抗氧化作用有关。     

心律平对缺血再灌注心脏保护作用的实验研究

目的 探讨心律平（抗心律失常药）对缺血再灌注心肌的保护效果.方法 大鼠24只,离体心脏灌注,随机分为试验组与对照组：2组均应用停跳液,心脏停跳后,停灌注120 min,再灌注30 min,实验组在停跳液中加入心律平.分别测定再灌注5,10,30 min时,左心室收缩功能（LVDPi）及冠脉流量（Vi）,检测冠脉流出液中CPK-MB、LDH、TnT量;再灌注30 min,取左心室前壁内膜,检查心肌超微结构变化.结果 再灌注5,10,30 min实验组左心肌收缩功能恢复均好于对照组;漏出液中CPK-MB、LDH、TnT含量均少于对照组组.实验组超微结构损害较对照组轻.结论 停跳液中加用心律平,可减少缺血再灌注损伤,有显著的心肌保护作用.     

3,4-二羟基苯乙酮对心肌保护作用的研究

目的研究心肌3,4-二羟基苯乙酮(青心酮)预处理和缺血预处理对离体大鼠心脏缺血/再灌注后心肌功能的影响。方法以离体大白鼠工作心脏模型,比较经青心酮预处理和缺血预处理,心肌缺血再灌注前后左室压(LVP)、左室舒张末期压(LVDEP)、左心室内压上升及下降最大速率(±dt/dpmax)、主动脉压(AP)、冠脉流量(CF)、主动脉流量(AF)和测定冠脉流出液乳酸脱氢酶(LDH),心肌三磷酸腺苷(ATP)含量及自灌注停搏液至完全停搏的时间(AT)。结果青心酮预处理和缺血预处理产生相似的心肌保护作用,明显促进心肌缺血再灌注后心肌功能的恢复,增进心脏的收缩功能、心肌ATP含量。结论青心酮预处理模拟体外循环的缺血再灌注损伤具有保护作用,该方法有临床应用价值。     

高渗灌注减轻正常及高血压大鼠心脏缺血再灌注损伤

目的：观察体外高渗灌注对正常及高血压大鼠心肌缺血及再灌注损伤的影响．方法：利用体外心脏逆行灌注装置将大鼠心脏在予以正常灌注液或高渗透压灌注液灌注后进行缺血及再灌注．监测缺血前后心肌功能、缺血后心肌肌酸激酶释放量,用高效液相加电化学法测定心肌儿茶酚胺释放量,用原子吸收光谱法测定再灌注后心肌钙离子含量．结果：高渗灌注可显著减轻正常及高血压大鼠心肌缺血损害,改善高血压大鼠缺血后心功能,减少心肌儿茶酚胺释放,但未能减少再灌注后心肌钙含量．结论：高渗灌注减轻心肌缺血与再灌注损害,其作用可能与减少心肌儿茶酚胺释放有关．     

异丙酚对离体大鼠心肌缺血/再灌注损伤的保护作用

目的观察异丙酚对离体大鼠心肌缺血/再灌注损伤的影响并从氧化应激和线粒体介导的凋亡方面探讨其作用机制。方法应用langendorff离体心脏灌注系统建立心肌缺血/再灌注损伤模型。40只SD大鼠随机分为正常对照组、缺血/再灌注模型(I/R)组、异丙酚15、30、60μmol.L-1组。除正常对照外,各组分别平衡灌注20min后,常温全心停灌25min,再灌注30min。Powerlab/8s仪记录各组平衡末、缺血前及再灌30min时的各项心功能指标并测定冠脉流出液中乳酸脱氢酶(LDH)、磷酸肌酸激酶(CK)活性;检测心肌线粒体活力、膜肿胀度、锰超氧化物岐化酶活性(Mn-SOD)和丙二醛(MDA)含量;原位末端转移酶标记法(TUNEL)检测心肌细胞凋亡;流式细胞术检测Bcl-2和Bax的表达,免疫组化法测定天冬氨酸特异的半胱氨酸蛋白酶(Caspase)-3,9,8蛋白的表达。结果与I/R组相比,异丙酚30、60μmol.L-1能明显改善缺血/再灌后的心功能,减弱冠脉流出液中LDH、CK的活性(P<0.05);心肌线粒体活力有所恢复,膜肿胀度减轻,升高Mn-SOD活性,MDA生成明显减少(P<0.05),心肌细胞凋亡明显减少,Bcl-2表达上调,Bax表达下调,Caspase-3,9阳性表达细胞数明显减少(P<0.05)。结论异丙酚明显减轻缺血/再灌所致的心肌线粒体的过氧化损伤,抑制线粒体途径的凋亡,可能是其心肌保护作用机制之一。     

3′-大豆苷元磺酸钠对心肌缺血/再灌注损伤及抗氧化作用的影响

目的利用离体心脏灌流模型,研究3′-大豆苷元磺酸钠对离体心脏缺血/再灌注损伤的保护作用,并探讨其抗氧化作用的机制。方法应用Langendorff离体心肌缺血/再灌注损伤模型,在灌流液中加入高、中、低剂量的3′-大豆苷元磺酸钠,测定再灌注过程中冠脉流量、左心室收缩压的变化;比色法测定心肌组织中LDH、SOD、GSH-Px的活性。结果3′-大豆苷元磺酸钠可使缺血/再灌注后心脏灌流量及左心室收缩压增大,使心肌组织中LDH、SOD、GSH-Px的活性升高。结论3′-大豆苷元磺酸钠对离体心脏缺血/再灌注损伤具有保护作用,其保护机制与其增强抗氧化作用有关。     

水杉总黄酮对豚鼠工作心脏缺血再灌注损伤的影响

目的　观察水杉总黄酮对缺血再灌注损伤心肌的保护作用。方法　采用豚鼠工作心脏缺血再灌注损伤模型 ,观察水杉总黄酮对缺血再灌注损伤心肌心功能以及生化指标的影响。结果　水杉总黄酮能明显改善缺血再灌注损伤心肌的舒缩功能 ,剂量依赖性地降低冠脉流出液中肌酸磷酸激酶以及乳酸脱氢酶的活性 ,减少缺血心肌组织中丙二醛的含量。结论　水杉总黄酮对缺血再灌注损伤心肌具有保护作用 ,其机制与其抗脂质过氧化有关     

芬太尼与瑞芬太尼预处理抗大鼠体外心肌缺血 再灌注损伤作用比较

目的 比较芬太尼与瑞芬太尼预处理对大鼠体外心脏功能及心肌缺血-再灌注损伤后的影响.方法 雄性SD大鼠50只,体重200～250 g,随机分为5组,麻醉后开胸取心脏,建立Langendorff大鼠体外心脏灌注模型.每组均灌注平衡20 min.对照组（CON）用95%氧气和5%二氧化碳饱和的K-H液持续灌注20 min,停灌30 min再灌注45 min.芬太尼预处理组（FPC1,FPC2）：缺血前用含芬太尼20或40 μg&#8226;L-1的95%氧气和5%二氧化碳饱和K-H液灌注20 min,全心缺血30 min,复灌45 min.瑞芬太尼预处理组(RPC1,RPC2)：瑞芬太尼浓度及灌注方法同芬太尼组.记录各组左室舒张末压（LVEDP）、左室收缩压（LVSP）及冠状动脉流量（CF）变化,测定平衡15 min后到再灌注后15 min内冠状动脉流出液乳酸脱氢酶（LDH）活性,测定再灌注后45 min时的心肌丙二醛（MDA）含量,同时取每组大鼠心肌做切片,在电镜下观察心肌细胞的超微结构.结果 在平衡20 min末,各组LVEDP,LVSP以及LDH的活性比较差异无显著性.与对照组比较,芬太尼及瑞芬太尼预处理组在灌注后各时间点LVEDP降低（均P＜0.01）,LVSP及CF升高（均P＜0.01）,灌注后15 min冠脉流出液LDH活性降低（均P＜0.01）,再灌注后45 min后心肌MDA含量降低（均P＜0.01）,梗死面积较小（均P＜0.05）,电镜下心肌结构破坏不明显;组内比较,高浓度处理组保护作用明显（P＜0.05）;组间比较瑞芬太尼组保护作用较好（P＜0.05）.结论 芬太尼和瑞芬太尼对体外大鼠全心缺血 再灌注损伤均有保护作用,且有浓度依赖性,相同浓度的瑞芬太尼与芬太尼比较保护作用更明显,二者对体外心肌心功能影响无差别.     

Cardioprotective effects of amlodipine in animal models of ischemia and reperfusion

The protective effect of amlodipine was studied in isolated blood-perfused cat hearts made globally ischemic for 60 min followed by reperfusion for 60 min. Ischemia-induced alterations of left ventricular developed pressure and compliance were monitored. Amlodipine produced significant decreases in myocardial oxygen consumption (6.2 +/- 0.4 to 4.4 +/- 0.4 ml of oxygen/min/100 g) and coronary vascular resistance, as assessed by changes in perfusion pressure (120 +/- 1 to 100 +/- 4 mm Hg). When administered before the onset of global ischemia, amlodipine decreased the development of ischemic contracture as reflected by a progressive increase in resting left ventricular diastolic pressure. The return of contractile function, 60 min after reperfusion, was improved significantly in amlodipine-treated hearts compared to controls and there was better maintenance of the tissue concentration of Na+, Ca2+, and K+. In a canine model of regional myocardial ischemia (6 h) followed by reperfusion, amlodipine at 150 microg/kg, administered 15 min before reperfusion (90 min), reduced infarct size expressed as a percentage of the area at risk (34.5 +/- 3.8% vs. 45.9 +/- 2.8%, p = 0.027). We conclude that amlodipine reduces myocardial ischemic injury by mechanism(s) that may involve a reduction in myocardial oxygen demand as well as by positively influencing transmembrane Ca2+ fluxes during ischemia and reperfusion.     

巴曲酶对抗狗心脏缺血/再灌损伤(英文)

目的:研究巴曲酶(Bat)对狗心脏缺血/再灌损伤的影响。方法:狗冠脉左前降枝结扎30 min后恢复血液灌注,于缺血前(Bat-Ⅰ组)或缺血后再灌前15min(Bat-Ⅱ组)静脉注射Bat(1 Bu·kg~(-1))。测定dp/dt_(max)和LVEDP及血浆CK和LDH及心肌MDA含量,观察心肌病理形态学改变。结果:I/R组动物缺血或再灌后死亡率高达65.0％,心肌损伤明显。Bat-Ⅰ和Bat-Ⅱ组动物的死亡率分别为30.0％和28.6％,P<0.05,心肌损伤减轻;血浆CK、LDH含量,LVEDP及心肌MDA含量降低; dp/dt_(max)和-dp/dt_(max)增加。结论:Bat可明显拮抗狗心脏缺血/再灌注损伤,改善心功能。     

硫化氢对离体大鼠心脏缺血/再灌注损伤的影响及机制初探

目的观察内源性CSE/H2S通路的改变以及给予H2S供体对缺血/再灌注心脏的影响,探讨该通路与心脏缺血/再灌注损伤的关系及作用机制。方法采用Langendorff离体灌流装置、通过停灌30min/复灌30min方式造成Wistar大鼠心肌缺血/再灌注损伤模型;采用外源性NaHS(40μmol.L-1)分别在停灌30min前(SIR)与停灌30min后处理(IRS)对缺血/再灌注心脏的影响。记录心脏收缩期左心室内压上升的最大变化速率(+dp/dtmax)、舒张期左心室内压下降的最大变化速率(-dp/dtmax)及左室内压差(LVP=左室收缩压-左室舒张压)。采用比色法检测灌流液中乳酸脱氢酶(LDH)、心肌MDA及SOD;采用比色法检测心肌胱硫醚-γ-裂解酶(CSE)活性;采用RT-PCR方法测定心肌组织CSEmRNA表达。结果与缺血/再灌注组(I/R)30min相比,SIR组及IRS组±dp/dtmax、LVP均增高,LDH降低;I/R组MDA水平高于对照组(CON)、SIR组及IRS组(P<0.05,P<0.01);IR组SOD活性低于SIR组及IRS组(P<0.05),但与CON组差别无显著性;I/R组大鼠心肌CSE活性低于CON组(P<0.05);而大鼠心肌CSEmRNA的表达与CON组差异无显著性。结论在缺血前后给予外源性NaHS均可改善因再灌注损伤引起的心肌收缩及舒张功能障碍;其作用机制可能是通过提高心肌SOD活性,增加氧自由基清除而拮抗缺血/再灌注引起的心功能及细胞膜损伤;心肌缺血/再灌注时内源性CSE活性抑制可能与心功能障碍及细胞损伤有关。     

新化合物TG6对心肌缺血/再灌注损伤的影响及机制研究

目的研究TG6对心肌缺血/再灌注损伤的保护作用及机制。方法采用整体大鼠心肌缺血/再灌注（I/R）实验,离体大鼠心脏低灌复灌实验和乳鼠心肌细胞缺氧/复氧损伤（H/R）实验等模型,以血清CK、LDH、T-SOD、MDA等为指标,研究TG6对心肌缺血再灌注损伤的保护作用。结果在整体大鼠心肌缺血再灌注损伤实验中,TG6显著减少I/R损伤后心肌梗死面积,减少血清中CK活力和MDA含量,减少LDH活力,增加T-SOD活力;在离体大鼠心脏低灌复灌实验中,TG6显著增加低灌复灌后心肌冠脉流量,减少心肌组织中MDA含量和CK、LDH外漏,提高心肌组织中T-SOD活力;在乳鼠心肌细胞H/R损伤实验中,TG6对正常生长条件下的细胞没有明显影响,提高Na2S2O4制备的心肌细胞H/R模型下细胞的存活率、降低细胞CK的释放率及细胞[Ca^2＋]i的含量。结论 TG6对心肌I/R损伤有一定的保护作用。     

内源性硫化氢参与缺血后处理减轻离体大鼠心脏缺血/再灌注损伤

目的探讨内源性硫化氢是否参与缺血后处理减轻大鼠心肌缺血/再灌注损伤。方法Sprague Dawley(SD)大鼠离体心脏Langendorff灌流,平衡20min,全心缺血30min,复氧灌注60min,在复灌即刻给与短暂停灌15s/复灌15 s循环4次造成心肌缺血后处理模型。预先给予胱硫醚-γ-裂解酶(cystanthionine-γ-lysase,CSE)抑制剂炔丙基甘氨酸(L-propargylglycine,PAG),以及给予PAG后加用外源性硫化氢供体NaHS后处理,观察它们对缺血后处理的影响。记录心率(HR)、左室发展压(LVDP)、冠脉流出量(CF);检测灌流液中乳酸脱氢酶(LDH)活性、心肌组织CSE活性、硫化氢的含量以及心肌梗死面积。结果缺血/再灌注组LVDP下降、冠脉灌流液中LDH活性明显增加、心肌梗死面积增加(vsControl组,P<0.05)。缺血后处理组LVDP升高、冠脉灌流液中LDH活性下降、心肌梗死面积缩小(vsIR组,P<0.05)。PAG加缺血后处理组心肌CSE活性及H2S生成下降、并且逆转了缺血后处理的作用,而外源性硫化氢供体NaHS后处理组H2S生成回升、LVDP升高、心肌梗死面积缩小(vsIR组,P<0.05)。结论内源性硫化氢参与大鼠心肌缺血后处理减轻缺血/再灌注损伤。     

Cardioprotection by streptozotocin-induced diabetes and insulin against ischemia/reperfusion injury in rats

The effects of streptozotocin (STZ)-induced diabetes (DM) and insulin on cardiac performance were investigated during reperfusion after low-flow ischemia in rats. Hearts were isolated 4 weeks after intravenous injection of STZ (65 mg/kg) or vehicle and retrogradely perfused in the presence (throughout the perfusion period) or absence of 1 U/L insulin using a Langendorff apparatus. Normothermic low-flow global ischemia was instituted by reducing the flow rate to 5% of baseline for 30 min, followed by reperfusion for 30 min. Rate pressure product (left ventricular developed pressure x heart rate) was calculated as an index of cardiac performance. Myocardial concentrations of adenine nucleotides, creatine phosphate (CP) and glycogen were measured. Insulin perfusion increased preischemic myocardial glycogen content in both DM and control hearts. Recovery of cardiac performance and myocardial CP concentrations in the absence of insulin was greater in the DM hearts than in controls during reperfusion. Insulin perfusion improved recovery of cardiac performance and elevated CP concentrations in both DM and control hearts. These results demonstrate greater cardioprotection against ischemia/reperfusion injury in the STZ-DM state and with insulin perfusion. These protective effects may be associated with augmented resynthesis of high-energy phosphates during reperfusion.     

Protective effects of ghrelin on ischemia/reperfusion injury in the isolated rat heart

Ghrelin, an endogenous ligand of the growth hormone secretagogue receptor, has been reported to have beneficial effects on cardiac function. The authors used the Langendorff model of ischemia/reperfusion (I/R) injury in isolated rat heart to determine whether ghrelin exerts direct cardioprotective effects. Also, the capacity of ghrelin to bind to sarcolemmal membrane fractions before and after ischemia and reperfusion was examined. Compared with vehicle administration, administration of ghrelin (100-10,000 pM) during the reperfusion period resulted in improvement in coronary flow, heart rate, left ventricular systolic pressure, and left ventricular end-diastolic pressure. Ghrelin also enhanced the rates of left ventricular contraction and relaxation after ischemia following reperfusion. Administration of ghrelin during reperfusion reduced myocardial release of lactate dehydrogenase and myoglobin, indicating protection against cardiomyocyte injury. In addition, ghrelin attenuated the depletion of myocardial ATP resulting from ischemia and reperfusion. A receptor-binding assay demonstrated that maximum binding capacity of ghrelin to sarcolemmal membranes was significantly increased after ischemia and was further increased after I/R. However, Scatchard analysis showed that the affinity of ghrelin for its receptor was not altered. The authors have concluded that administration of ghrelin during reperfusion protects against myocardial I/R injury. The cardioprotective effects are independent of growth hormone release and likely involve binding to cardiovascular receptors, a process that is upregulated during I/R.     

Experimental conditions determine effects of ascorbic acid on reperfusion injury: comparison of tissue damage with hemodynamic parameters in rat isolated hearts.

Restoration of coronary blood flow after myocardial ischemia is always a matter of urgency, but the resulting surgical or drug-induced reperfusion of ischemic tissue is often associated with myocardial functional disturbances and tissue injury. The present study was carried out to select experimental conditions under which optimal effects of antioxidants can be observed on the adverse effects of reperfusion of ischemic myocardium. The release of lactate dehydrogenase (LDH) and changes in hemodynamic parameters were compared in two models of cardiac reperfusion injury in rat isolated hearts. LDH release from electrically-stimulated hearts perfused under constant flow and with initial (5 min) reperfusion in calcium-free buffer was greater than that from hearts perfused under constant pressure in which ischemia was induced by reduced flow. Combined SOD+catalase was a weak inhibitor of LDH release in both models, ascorbic acid being more potent under constant pressure than under constant flow conditions. A longer ischemic period enhanced the inhibitory effect of ascorbate. Contractility and ventricular end-diastolic pressure recovered slowly during perfusion under constant flow and brief calcium removal, but remained unphysiological under constant pressure. SOD+catalase had no effect on hemodynamic parameters. Ascorbic acid exacerbated ischemia+reperfusion-induced changes in contractility, ventricular pressure, heart rate and coronary flow under constant pressure, but facilitated recovery of contractility on reperfusion under constant flow and brief calcium removal. In studies on antioxidants, different experimental conditions appear to be necessary to observe beneficial effects on tissue damage on the one hand and on hemodynamics on the other. Mild to moderate ischemia, with sustained pacemaker activity, appears to be the condition under which antioxidants provide hemodynamic improvement. In isolated rat hearts, biochemical parameters of tissue damage may be misleading for the effects of antioxidants.     

Effect of inosine in the normal and reperfused rat heart.

Inosine is a positive inotropic agent and dilates coronary blood vessels. During ischemia, inosine infusion increases blood flow, resulting in decreased myocardial damage. We wished (a) to determine inosine's effect in isolated rat hearts and (b) to determine if inosine attenuates myocardial dysfunction after transient global ischemia. Developed left ventricular pressure (LVP), LV dP/dt, and coronary perfusion pressure were monitored in hearts receiving Krebs-Henseleit buffer (KHB) (n = 10) or KHB + 2 mM inosine (n = 4). KHB + 2 mM inosine significantly reduced coronary perfusion pressure by 21% but had no effect on developed LVP or LV dP/dt. Hearts receiving KHB (n = 6) or KHB + 2 mM inosine (n = 5) were subjected to 15-min global ischemia followed by 30-min reperfusion with KHB. Recovery of LVP, LV dP/dt, the incidence of arrhythmias, and the time to peak recovery of developed LVP was not different between groups. In two additional hearts, KHB + 2 mM inosine administered during reperfusion had no effect on developed LVP, LV dP/dt, or coronary perfusion pressure. Thus, unlike other preparations, inosine pretreatment did not significantly affect the time course of postischemic functional recovery of rat myocardium.     

丹金合剂对大鼠心肌缺血再灌注损伤的保护作用

目的:探讨丹金合剂对大鼠心肌缺血再灌注损伤的保护作用。方法:通过结扎大鼠冠状动脉左前降支(LAD)制成心肌缺血再灌注损伤模型,观察丹金合剂在心肌缺血再灌注状态下对心功能及心肌组织酶的影响。结果:丹金合剂能显著的升高大鼠心肌缺血再灌注引起的左室内压(LVSP)、左室内压最大上升与下降速率(dp/dtmax);降低心肌丙二醛(MDA)含量,增高超氧化物歧化酶(SOD)、Na 、K -ATPase,Ca2 、Mg2 -ATPase的活力。结论:丹金合剂对大鼠心肌缺血再灌注损伤具有保护作用。